ReviewOncogene2003
Ocular neovascularization: a valuable model system.
Review in Oncogene, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 98 citations in OpenAlex.
- Article
- CCRL2 Modulates Physiological and Pathological Angiogenesis During Retinal Development.Frontiers in cell and developmental biology · 2021Article
- Mitophagy Protects the Retina Against Anti-Vascular Endothelial Growth Factor Therapy-Driven HypoxiaFrontiers in cell and developmental biology · 2021Article
- Canonical Wnt Signaling Promotes Neovascularization Through Determination of Endothelial Progenitor Cell Fate via Metabolic Profile Regulation.Stem cells (Dayton, Ohio) · 2019Article
- Therapeutic Effects of a Novel Phenylphthalimide Analog for Corneal Neovascularization and Retinal Vascular Leakage.Investigative ophthalmology & visual science · 2018Article
- Implantable tissue isolation chambers for analyzing tumor dynamics in vivo.Lab on a chip · 2016Article
- Drug discovery in ophthalmology: past success, present challenges, and future opportunities.BMC ophthalmology · 2016Review
- Tubedown regulation of retinal endothelial permeability signaling pathways.Biology open · 2015Article
- Development of an experimental model of proliferative retinopathy by intravitreal injection of VEGF165.Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics · 2014Article
- Emergence of dual VEGF and PDGF antagonists in the treatment of exudative age-related macular degeneration.Expert review of ophthalmology · 2013Article
- Inhibition of choroidal and corneal pathologic neovascularization by Plgf1-de gene transfer.Investigative ophthalmology & visual science · 2012Article
- Article
- A potential therapeutic strategy for inhibition of ocular neovascularization with a new endogenous protein: rhEDI-8t.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2012Article
- Article
- Macrophage metalloelastase (MMP-12) deficiency mitigates retinal inflammation and pathological angiogenesis in ischemic retinopathy.PloS one · 2012Article
- Co-culture of Retinal and Endothelial Cells Results in the Modulation of Genes Critical to Retinal Neovascularization.Vascular cell · 2011Article
- Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy.Nature medicine · 2010Article
- Rapid remodeling of airway vascular architecture at birth.Developmental dynamics : an official publication of the American Association of Anatomists · 2010Article
- Consequences and utility of the zinc-dependent metalloprotease activity of anthrax lethal toxin.Toxins · 2010Review
- The Flk1-myr::mCherry mouse as a useful reporter to characterize multiple aspects of ocular blood vessel development and disease.Developmental dynamics : an official publication of the American Association of Anatomists · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
There is no unique formula for angiogenesis. Instead there is a large group of potential participating proteins that interact in complex ways. Depending upon the surrounding cell types and the relative expression levels of angiogenesis-related proteins, the 'angiogenesis cascade' can vary. Therefore, it is valuable to study and compare the role of proteins in several well-characterized vascular beds. The eye provides a useful model system, because it contains several vascular beds sandwiched between avascular tissue. This allows for unequivocal identification and quantitation of new vessels. Retina-specific promoters combined with inducible promoter systems provide a means to regulate the expression of proteins of interest. As a relatively isolated compartment, the eye also provides advantages for gene transfer. By gaining insight regarding the molecular signals involved in various types of ocular angiogenesis, general concepts can emerge that may apply to other settings, including tumor angiogenesis. One concept that has emerged is that despite participation of multiple stimulatory factors for ocular neovascularization, VEGF plays an essential role and interruption of VEGF signaling is an important therapeutic strategy. Another concept is that while most studies have focused on prevention of ocular neovascularization, regression of new vessels is desirable and is achievable with at least three agents, combretastatin A-4 phosphate, pigment epithelium-derived factor, and angiopoietin-2. Finally, endostatin and angiostatin, which have been sources of controversy because of inconsistent results in tumor models, have been shown to have good efficacy when delivered by gene transfer in models of ocular neovascularization. These results provide leads for new ocular treatments and perspective for evaluation of studies of neovascularization in extraocular tissues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.